• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Wellcome Trust to launch $317 million investment business

Wellcome Trust to launch $317 million investment business

March 21, 2012
CenterWatch Staff

The Wellcome Trust’s board of governors has approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors.

The business's initial capital will be $317 million, drawn from the Wellcome Trust's endowment. The business is currently operating under the working title Project Sigma, and a name and brand identity will be announced shortly.

Sigma will be a directly owned and managed business that will seek to deliver attractive returns on the capital it invests. It will provide financial resources with which to advance the Wellcome Trust's vision of achieving extraordinary improvements in human and animal health by supporting the brightest minds in biomedical research and the medical humanities.

"The Wellcome Trust is known as an investor that takes a long-term view. Sigma will extend this successful approach to direct investments in emerging healthcare technologies, to give small and medium-sized companies the support they require to fulfill their potential,” said Sir Mark Walport, director, Wellcome Trust.

Sigma will also enable Wellcome Trust to take and retain ownership positions in the companies. It will be able to contribute proactively to their development over the long term, for example by bringing together complementary expertise from different companies and scientific fields.

Although Sigma has the primary goal of generating excellent returns for the Wellcome Trust, its investments will also provide emerging businesses in the healthcare sector with a valuable new source of funding and guidance. This will help them to turn exciting advances in the life sciences into diagnostics and therapies that contribute to improved patient care.

Sigma will be headed by Nigel Keen as chairman and Martin Murphy as CEO. Wellcome Trust is in the final stages of closing agreements for operation of the Sigma business.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing